Stock Market & Financial Investment News

News Breaks September 4, 2012 07:06 EDT BLRX BioLineRx signs license agreement with Biokine Therapeutics for BL-8040 BioLineRx announced that it has signed an exclusive, worldwide license agreement with Biokine Therapeutics, a Clal Biotechnology Industries portfolio company, for the development and commercialization of BL-8040, formerly BKT-140, a Phase II ready drug candidate for the treatment of acute myeloid leukemia, as well as other types of hematological cancer. News For BLRX From The Last 14 Days Check below for free stories on BLRX the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 21, 2013 07:44 EDT BLRX Sachs Associates to host a forum Subscribe for More Information May 17, 2013 12:02 EDT BLRX BioLineRx enters at-the-market offering agreement with Stifel Nicolaus & Co. Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.